As a second-line treatment for RAS/BRAF wild-type colorectal cancer, treatment regimens using anti-EGFR antibodies are recommended by regional guidelines as one of the standard treatments [21,22,23]. The gene discussed is BRAF; the disease is colorectal cancer.